336 related articles for article (PubMed ID: 34561555)
1. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model.
Zhang H; Xie W; Zhang Y; Dong X; Liu C; Yi J; Zhang S; Wen C; Zheng L; Wang H
Cancer Gene Ther; 2022 May; 29(5):456-465. PubMed ID: 34561555
[TBL] [Abstract][Full Text] [Related]
2. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity.
Mei S; Peng S; Vong EG; Zhan J
Int Immunopharmacol; 2024 Feb; 128():111579. PubMed ID: 38278066
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
Chaurasiya S; Yang A; Kang S; Lu J; Kim SI; Park AK; Sivanandam V; Zhang Z; Woo Y; Warner SG; Fong Y
Oncoimmunology; 2020; 9(1):1729300. PubMed ID: 32158622
[TBL] [Abstract][Full Text] [Related]
4. RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment.
Meng Y; Liu H; Zhu H; Zhang W; Sun D; Han X; Liu Y; Luo G
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212125
[TBL] [Abstract][Full Text] [Related]
5. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
6. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
[TBL] [Abstract][Full Text] [Related]
8. Priming with oncolytic adenovirus followed by anti-PD-1 and paclitaxel treatment leads to improved anti-cancer efficacy in the 3D TNBC model.
Kuryk L; Mathlouthi S; Wieczorek M; Gad B; Rinner B; Malfanti A; Mastrotto F; Salmaso S; Caliceti P; Garofalo M
Eur J Pharm Biopharm; 2024 Jun; 199():114300. PubMed ID: 38697488
[TBL] [Abstract][Full Text] [Related]
9. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
Yang Z; Sun JK; Lee MM; Chan MK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
[TBL] [Abstract][Full Text] [Related]
10. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
[TBL] [Abstract][Full Text] [Related]
11. The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade.
Najafi S; Majidpoor J; Mortezaee K
Biomed Pharmacother; 2023 May; 161():114436. PubMed ID: 36841031
[TBL] [Abstract][Full Text] [Related]
12. Ponatinib delays the growth of solid tumours by remodelling immunosuppressive tumour microenvironment through the inhibition of induced PD-L1 expression.
Barnwal A; Tamang R; Sanjeev Das ; Bhattacharyya J
Br J Cancer; 2023 Oct; 129(6):1007-1021. PubMed ID: 37400678
[TBL] [Abstract][Full Text] [Related]
13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
14. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
Clubb JHA; Kudling TV; Girych M; Haybout L; Pakola S; Hamdan F; Cervera-Carrascon V; Hemmes A; Grönberg-Vähä-Koskela S; Santos JM; Quixabeira DCA; Basnet S; Heiniö C; Arias V; Jirovec E; Kaptan S; Havunen R; Sorsa S; Erikat A; Schwartz J; Anttila M; Aro K; Viitala T; Vattulainen I; Cerullo V; Kanerva A; Hemminki A
Front Immunol; 2023; 14():1060540. PubMed ID: 36817448
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
[TBL] [Abstract][Full Text] [Related]
16. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
[TBL] [Abstract][Full Text] [Related]
17. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
18. Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.
Shi G; Yang Q; Zhang Y; Jiang Q; Lin Y; Yang S; Wang H; Cheng L; Zhang X; Li Y; Wang Q; Liu Y; Wang Q; Zhang H; Su X; Dai L; Liu L; Zhang S; Li J; Li Z; Yang Y; Yu D; Wei Y; Deng H
Mol Ther; 2019 Jan; 27(1):244-260. PubMed ID: 30527756
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
[TBL] [Abstract][Full Text] [Related]
20. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
